HOME >> BIOLOGY >> NEWS
Bacteria's natural foe fights drug-resistant infections

in nursing homes and day-care centers, where drug-resistant strains thrive.

Until now, there has been no strategy to remove the reservoir of S. pneumoniae from the noses and throats of humans. Yet, this "home base" provides an excellent target for controlling infections.

"This enzyme will kill pneumococci on mucous membranes within seconds," says Jutta Loeffler, M.D., first author of the paper and a postdoctoral fellow at Rockefeller. "By treating individuals carrying this bacterium with the enzyme, you could significantly reduce the reservoir of these bugs in the population and consequently reduce infection rates."

Such a decline in the number of worldwide infections would lessen the need for traditional antibiotics and subsequently ease the mounting drug-resistance problem.

Bacteriophage, or phage, can be found just about anywhere: in sewage and soil and any other locations where bacteria are found. As part of their normal lifecycle, these tiny viruses infect, replicate, then burst out of bacteria before infecting their next host.

Special phage enzymes, which punch holes in the bacterial cell wall, ensure the phage a rapid exit; without this outer layer of protection the bacteria essentially cannot hold themselves together, and, they explode.

Fischetti discovered that the phage enzymes also work when applied to the outside of the bacterial cells: by adding a few drops of phage enzyme to a test tube of millions of bacteria, he found that he could kill nearly all of them within a few seconds.

Because phage enzymes are specific for the species or strain of bacterium from which they were produced, cultivating a tailor-made killer for any bacterium of interest may be possible. Last February, for example, Fischetti and colleagues reported the isolation of a phage enzyme specific for Group A streptococci, an infectious pathogen that causes strep throat and flesh-eating disease. Human clinical trials testing the
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
6-Dec-2001


Page: 1 2 3 4

Related biology news :

1. Bacterias iron-absorbing mechanisms may open gates for new types of antibiotics
2. Posters highlight water, energy and other natural resource research
3. Hunting illusive signs of natural selection
4. University of Arizona licenses patent for natural fungicide
5. Improving crops without genetic modification natural variation holds the key
6. Using statistics to decipher secrets of natural mutation
7. New designed paclitaxel analog kills more cancer cells than natural product
8. After natural disasters, the risk of infection, epidemics from dead bodies is negligible
9. Pearly mussels: One of North Americas natural jewels is disappearing
10. Unnatural light-dark cycles expose duelling circadian clocks
11. St. Jude researchers create image of enzyme that orchestrates natural genetic engineering

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
Cached News: